Corporate
Agios Wins Historic FDA Approval: AQVESME Becomes First Oral Therapy for Broad Thalassemia Population
Dec 24, 2025
You're signed outSign in or to get full access.
AP
AGIOS PHARMACEUTICALS (AGIO)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering AGIOS PHARMACEUTICALS.